Inhibition of leukemic cells by valproic acid, an HDAC inhibitor, in xenograft tumors

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 733-740

  Zhang, Zhihua ^a   Hao, Changlai ^a   Wang, Lihong ^a   Liu, Peng ^b   Zhao, Lei ^a   Zhu, Cuimin ^a   Tian, Xia ^c  

^a CHENGDE MEDICAL COLLEGE   (China)

^b Department of Medical Oncology   (China)

^c Rizhao Municipal People's Hospital   (China)

Author keywords

Acute myeloid leukemia; AML1 ETO; E2F; p21; Valproic acid

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; PROTEIN P21; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL STRAIN; CELL STRAIN KASUMI 1; CONTROLLED STUDY; FEMALE; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; P21 GENE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TUMOR XENOGRAFT; UPREGULATION;

EID: 84879350714     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S46135     Document Type: Article

References (28)

1. Hug BA, Lazar MA. ETO interacting proteins. Oncogene. 2004;23: 4270-4274.
2. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770-1783.
3. Lee YM, Sicinski P. Targeting cyclins and cyclin-dependent kinases in cancer: lessons from mice, hopes for therapeutic applications in human. Cell Cycle. 2006;5:2110-2114.
4. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13-18.
5. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem. 2000;275:651-656.
6. Ogino S, Nosho K, Shima K, et al. p21 expression in colon cancer and modifying effects of patient age and body mass index on prognosis. Cancer Epidemiol Biomarkers Prev. 2009;18:2513-2521.
7. Allan LA, Duhig T, Read M, Fried M. The p21(WAF1/CIP1) promoter is methylated in Rat-1cells: stable restoration of p53-dependent p21(WAF1/CIP1) expression after transfection of a genomic clone containing the p21(WAF1/CIP1) gene. Mol Cell Biol. 2000;20:1291-1298.
8. Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood. 2002;99:2291-2296.
9. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol. 2005;33:53-61.
10. Rosato RR, Almenara JA, Cartee L, Betts V, Chellappan SP, Grant S. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol Cancer Ther. 2002;1:253-266.
11. Sasakawa Y, Naoe Y, Inoue T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937cells in vitro and in vivo. Biochem Pharmacol. 2002;64:1079-1090.
12. De Schepper S, Bruwiere H, Verhulst T, et al. Inhibition of histone deacetylases by chlamydocin induces apoptosis and proteasome-mediated degradation of survivin. J Pharmacol Exp Ther. 2003;304: 881-888.
13. Zhao L, Zhang ZH, Zhu CM et al. Inhibitory effect of valproic acid on cell cycle of Kasumi-1 cell line and its mechanism. Zhonghua Xue Ye Xue Za Zhi. 2008 Dec;29(12):802-805. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19176032.
14. Davie JR. Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev. 1988;8:173-178.
15. Kouzarides T. Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev. 1999;9:40-48.
16. Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol. 2004;338:17-31.
17. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998;12:599-606.
18. Duan H, Heckman CA, Boxer LM. Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol. 2005;25:1608-1619.
19. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769-784.
20. Batty N, Malouf GG, Issa JP. Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 2009;280:192-200.
21. Green SR, Choudhary AK, Fleming IN. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. Br J Cancer. 2010;103:1391-1399.
22. Slack JL. The biology and treatment of acute progranulocytic leukemia. Curr Opin Oncol. 1999;11:9-13.
23. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008;10:e19.
24. Milutinovic S, Knox JD, Szyf M. DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21(WAF1/CIP1/sdi1). J Biol Chem. 2000;275:6353-6359.
25. Lohr K, Moritz C, Contente A, Dobbelstein M. p21/CDKN1A mediates negative regulation of transcription by p53. J Biol Chem. 2003;278: 32507-32516.
26. Jin JS, Tsao TY, Sun PC, Yu CP, Tzao C. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. Pathol Oncol Res. 2012;18:713-720.
27. Liu S, Klisovic RB, Vukosavljevic T, et al. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. J Pharmacol Exp Ther. 2007;321(3):953-960.
28. Peterson LF, Yan M, Zhang DE. The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO. Blood. 2007 May 15;109(10):4392-4398.